The ELEVATE Study shows that atogepant effectively prevents episodic migraine.

Published Date: 24 Apr 2023

Atogepant (Qulipta) performed better than a placebo in the ELEVATE study for preventing episodic migraine in patients who were resistant to other treatments.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Refractory Multiple Myeloma Responsive to Immunotherapy Plus Low-Dose Radiotherapy

2.

Pre-operative evaluation of ovarian cancer patients using DWI-MRI is helpful.

3.

Is Vitamin D a Key to Better Breast Cancer Survival?

4.

Immunotherapy after surgery is good for patients with advanced cancer

5.

As compared to proton therapy, proton therapy is very effective in treating esophageal cancer.


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot